Mission BioCapital

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Mediar Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. It specializes in developing antibody-based therapeutics targeting key fibrotic mediator proteins involved in fibrosis, aiming to halt and potentially reverse this condition in chronically damaged organs. The company operates at the pre-clinical stage.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

Mediar Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. It specializes in developing antibody-based therapeutics targeting key fibrotic mediator proteins involved in fibrosis, aiming to halt and potentially reverse this condition in chronically damaged organs. The company operates at the pre-clinical stage.

Totient Inc. is an AI-driven biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in using advanced machine learning and immunoinformatics to analyze complex datasets in the field of drug discovery and development. It focuses on identifying novel tissue-specific antigens and reconstructing high-affinity antibody therapeutics from tissues impacted by cancer, autoimmune diseases, and infections. By leveraging its platform's unique capabilities, Totient aims to quickly and accurately identify potent antibody candidates suitable for a variety of therapeutic applications, including cell therapies and bispecific antibodies. This innovative approach positions the company to address significant medical challenges in multiple areas of healthcare.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. It specializes in the development of advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and various materials. The company offers a multi-modal coherent Raman scattering microscope aimed at research and development as well as medical applications. Invenio Imaging's innovative platform technology is designed to facilitate intraoperative histology by providing high-resolution imaging that allows for the examination of specimens from multiple sites within a surgical cavity. The company was established based on research conducted by Professor Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.